Joseph P. Hagan - Jan 18, 2024 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Chief Executive Officer, Director
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
Jan 18, 2024
Transactions value $
-$17,359
Form type
4
Date filed
1/18/2024, 08:22 PM
Previous filing
Jan 17, 2024
Next filing
May 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGLS Common Stock Sale -$17.4K -14.6K -20.34% $1.19 57.1K Jan 18, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person.